Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

SphingoTec GmbH

SphingoTec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's assay portfolio includes sphingotest® bio-ADM® the assay for bioactive adrenomedullin, a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, sphingotest® penKid®, the assay for proenkephalin, a unique biomarker for real-time assessment of kidney function and IB10 sphingotest® DPP3, an assay for Dipeptidyl Peptidase 3, a unique biomarker for signaling pathway disruptions leading to acute organ dysfunction. Along with the Nexus IB10 POC platform by its subsidiary Nexus Dx Inc. (San Diego, CA, USA) acquired from Samsung in 2018, sphingotec markets a portfolio of established and novel biomarkers for acute care. In addition, sphingotec developed a portfolio of novel biomarkers, which predict the risks of obesity, breast cancer and cardiovascular diseases. *


Period Start 2002-01-01 established
  Group SphingoTec (Group)
Products Industry diagnostics (medical/biological)
  Industry 2 sphingotest® bio-ADM®
Persons Person Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director)
  Person 2 Plum, Achim (SphingoTec 202004– Managing Director + Chief Commerical Officer before Curetis + Siemens + Epigenomics)
Region Region Hennigsdorf
  Country Germany
  Street 15A Neuendorfstr.
  City 16761 Hennigsdorf
  Tel +49-3302-2056-50
    Address record changed: 2019-12-24
Basic data Employees A: 1 to 10 (2017-09-07)
    * Document for �About Section�: SphingoTec GmbH. (12/16/19). "Press Release: SphingoTec’s Proprietary Biomarker bio-ADM Detects Residual Congestion in Patients with Heart Failure". Hennigsdorf.
Record changed: 2020-04-16


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for SphingoTec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top